Journals / Turkish Journal of Endocrinology and Metabolism / 2020 / Cilt: 24 - Sayı: 4

Glucagon-Like Polypeptide-1 and Brain

Glukagon Benzeri Polipeptid-1 ve Beyin

Pages
343–355
Publication Date
2022-11-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Herein,the effects of glucagon-like polypeptide-1 on the centralnervous system will be discussed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Glucagon-like polypeptide-1 has specific effects on the central nervous system, including regulation of glucose metabolism, positive cardiovascular effects, slowing intestinalmotility, immune modulation, and regulation of appetite andenergy expenditure.
📊
Key Findings & Data:Recently, positive effects of GLP-1 onbrain energy utilization, inhibition and restoration of neurodegeneration, response to stress, and protection againstischemic neuron damage have been demonstrated.
💡
Conclusion & Impact:Herein,the effects of glucagon-like polypeptide-1 on the centralnervous system will be discussed.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Glucagon-like polypeptide-1 has specific effects on the central nervous system, including regulation of glucose metabolism, positive cardiovascular effects, slowing intestinalmotility, immune modulation, and regulation of appetite andenergy expenditure. Recently, positive effects of GLP-1 onbrain energy utilization, inhibition and restoration of neurodegeneration, response to stress, and protection againstischemic neuron damage have been demonstrated. Herein,the effects of glucagon-like polypeptide-1 on the centralnervous system will be discussed.

Özet

Glukagon benzeri peptid 1’in glukoz bağımlı insülin sekresyonu, beta hücre proliferasyonu, glukagon sekresyon inhibiyonu ile hepatik glukoz çıkışının azalması gibi metabolik etkilerinin yanında kardiyovasküler sistem üzerine olumlu etkiler, gastrointestinal motilitede yavaşlama, immunomodülasyon gibi etkileri olduğu bilinmektedir. Son zamanlarda santral sinir sistemi üzerine de belirgin etkiler gösterdiği saptanmıştır. Santral etkiler esas olarak iştah regülasyonu ve metabolizma üzerine olan etkilerin dışında beyin enerji kullanımının düzenlenmesi, nörodejenerasyonun önlenmesi ve düzeltilmesi, iskemik nöron hasarına karşı koruma ve organizmanın strese olan cevabının düzenlenmesi şeklinde sıralanabilir. Burada glukagon benzeri peptid 1’in santral sinir sistemi üzerine olan etkileri tartışılacaktır.

🔖

Cite This Article

BAKINER, O. S., ÖZŞAHİN, A. K. (2022). Glucagon-Like Polypeptide-1 and Brain. Turkish Journal of Endocrinology and Metabolism, Cilt: 24 - Sayı: 4, 343–355. https://ajindex.com/articles/605357

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013
  2. [Crossref] [PubMed] 2. Smith NK, Hackett TA, Galli A, Flynn CR. GLP-1: Molecular mechanisms and outcomes of a complex signaling system. Neurochem Int. 2019
  3. [Crossref] [PubMed] [PMC] 3. Fuchs H, Binder R, Greischel A. Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats. Biopharm Drug Dispos. 2009
  4. [Crossref] [PubMed] 4. Holt MK, Richards JE, Cook DR, Brierley DI, Williams DL, Reimann F, Gribble FM, Trapp S. Preproglucagon neurons in the nucleus of the solitary tract are the main source of brain GLP-1, mediate stress-induced hypophagia, and limit unusually large intakes of food. Diabetes. 2019
  5. [Crossref] [PubMed] [PMC] 5. Nishizawa M, Nakabayashi H, Uehara K, Nakagawa A, Uchida K, Koya D. Intraportal GLP-1 stimulates insulin secretion predominantly through the hepatoportal-pancreatic vagal reflex pathways. Am J Physiol Endocrinol Metab. 2013
  6. E376-E387. [Crossref] [PubMed] 6. Merchenthaler I, Lane M, Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol. 1999
  7. [Crossref] [PubMed] 7. Alhadeff AL, Rupprecht LE, Hayes MR. GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology. 2012
  8. [Crossref] [PubMed] [PMC] 8. Lockie SH, Heppner KM, Chaudhary N, Chabenne JR, Morgan DA, Veyrat-Durebex C, Ananthakrishnan G, Rohner-Jeanrenaud F, Drucker DJ, DiMarchi R, Rahmouni K, Oldfield BJ, Tschöp MH, Perez-Tilve D. Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling. Diabetes. 2012
  9. [Crossref] [PubMed] [PMC] 9. Ahmad K, Baig MH, Mushtaq G, Kamal MA, Greig NH, Choi I. Commonalities in biological pathways, genetics, and cellular mechanism between Alzheimer disease and other neurodegenerative diseases: an in silico-updated overview. Curr Alzheimer Res. 2017
  10. [Crossref] [PubMed] [PMC] 10. de la Monte SM. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res. 2012
  11. [Crossref] [PubMed] [PMC] 11. Frölich L, Blum-Degen D, Bernstein HG, Engelsberger S, Humrich J, Laufer S, Muschner D, Thalheime